How Much Does Dayvigo (Lemborexant) Cost in District of Columbia in 2026?

Dayvigo Retail Pricing Across District of Columbia Pharmacies

The gap between what Eisai lists and what patients actually pay is significant. Eisai's wholesale acquisition cost for Dayvigo remains $320 per month in 2026, but the average cash-pay price at DC retail pharmacies is roughly $85 per month. That difference reflects pharmacy-level negotiation, discount programs, and competitive pricing among local independents and chain pharmacies.

Prices vary by location. A CVS in Georgetown may quote differently than a Rite Aid in Anacostia, and an independent pharmacy in Adams Morgan could beat both. Patients without insurance should call at least three pharmacies before filling. GoodRx-style discount platforms often surface prices between $70 and $110 for a 30-day supply of lemborexant 5 mg or 10 mg tablets in the District. The FDA-approved prescribing information specifies two strengths (5 mg and 10 mg), and pricing at retail does not typically differ between them.

Patients should also ask pharmacists about 90-day fills. Some DC pharmacies offer per-tablet discounts on 90-day supplies that bring the effective monthly cost below $75. This approach works best for patients on a stable dose who have been tolerating the medication for at least 30 days.

DC Medicaid Coverage for Dayvigo

District of Columbia Medicaid covers Dayvigo, but it requires prior authorization (PA). This is standard for branded sleep medications. The PA process typically asks prescribers to document that the patient has tried and failed at least one generic alternative, such as generic zolpidem or generic suvorexant (which became available after Belsomra's patent expiration).

DC's Medicaid program is administered through managed care organizations (MCOs), and each MCO may have slightly different step-therapy requirements. In practice, most DC MCOs require documentation of an inadequate response to or intolerance of a first-line generic hypnotic before approving Dayvigo. The American Academy of Sleep Medicine's 2017 clinical practice guideline notes that orexin receptor antagonists are recommended for sleep-maintenance insomnia, which can support the PA submission.

The PA turnaround in DC typically runs 48 to 72 hours. If denied, prescribers can file a peer-to-peer review. Patients enrolled in the DC Healthcare Alliance (the District's program for residents who do not qualify for traditional Medicaid) should confirm formulary status directly with their assigned MCO, as Alliance formularies may differ from standard Medicaid preferred drug lists.

Insurance Coverage: Commercial Plans in DC

Most major commercial insurers operating in DC place Dayvigo on a Tier 3 (preferred brand) or Tier 4 (non-preferred brand) formulary position. CareFirst BlueCross BlueShield, the dominant commercial insurer in the District, typically lists Dayvigo on Tier 3 with prior authorization requirements similar to Medicaid's step-therapy protocols.

Copays on Tier 3 plans generally range from $35 to $75 per month. Tier 4 placement can push copays to $75 to $150. Patients with high-deductible health plans (HDHPs) may face the full retail price until meeting their deductible, making the Eisai savings card (discussed below) especially valuable during the deductible phase.

The Federal Employees Health Benefits (FEHB) program covers a large share of DC's insured population. FEHB plan formularies vary by carrier, but most FEHB plans do cover Dayvigo. Federal employees should check their specific plan's formulary on the OPM plan comparison tool and confirm tier placement before filling. The SUNRISE-1 trial, published in JAMA Network Open, demonstrated that lemborexant 5 mg and 10 mg significantly improved sleep onset and sleep maintenance versus placebo in adults with insomnia disorder (N=1,006), with improvements in latency to persistent sleep of 10.7 and 12.6 minutes respectively over placebo 1. This efficacy data frequently supports PA approvals.

How the Eisai Savings Card Works in DC

Eisai offers a manufacturer copay savings card for Dayvigo that can reduce out-of-pocket costs to as low as $0 per month for eligible commercially insured patients. The card is not valid for patients covered by Medicare, Medicaid, TRICARE, or any other federal or state government-funded program.

Here is how to use it in DC. Patients enroll online or receive a card from their prescriber. At the pharmacy counter, the card is processed as a secondary insurance. If the primary insurer approves the claim, the savings card covers the remaining copay up to the program's maximum benefit (typically $150 per fill, though terms may change annually). For a patient facing a $50 Tier 3 copay, the card would bring the cost to $0.

The savings card does have annual limits. In 2026, the program caps total annual savings at $1,800 per patient. For a patient using the card monthly, that allows up to $150 per month in copay assistance across 12 fills. Patients should re-enroll each calendar year and confirm current terms on Eisai's website.

One important limitation: the card does not apply during the deductible phase of some HDHPs if the plan requires the patient to pay full price before coverage activates. Some plans accept manufacturer copay cards toward the deductible; others do not. DC patients with HDHPs should call their insurer's pharmacy benefits line to confirm whether copay card payments count toward deductible accumulation.

Compounded Lemborexant in District of Columbia

Compounded lemborexant is available in DC through licensed 503A compounding pharmacies. Under federal law (the Drug Quality and Security Act, Section 503A), a 503A pharmacy may compound a copy of an FDA-approved drug when a prescriber writes a patient-specific prescription and a clinical need exists, such as a dose form not commercially available or an allergy to an inactive ingredient in the branded product.

DC does not have state-level restrictions that prohibit 503A compounding of lemborexant beyond federal requirements. Patients seeking compounded lemborexant should ensure the pharmacy holds a valid DC Board of Pharmacy compounding license. Pricing for compounded formulations varies widely but can be lower than branded Dayvigo. Some compounding pharmacies in the DC metro area advertise lemborexant capsules or sublingual preparations.

A clinical note: compounded drugs are not FDA-approved products. They do not undergo the same manufacturing, testing, and quality assurance processes as FDA-approved Dayvigo. The FDA has stated that compounded drugs should be used only when a medical need cannot be met by an FDA-approved product. Patients and prescribers should weigh cost savings against the absence of bioequivalence data when considering compounded lemborexant.

Telehealth Prescribing of Dayvigo in DC

DC permits telehealth prescribing of Dayvigo. Lemborexant is a Schedule IV controlled substance under the DEA classification, and DC law allows Schedule IV prescriptions via telehealth with appropriate documentation. Post-pandemic federal telehealth flexibilities for controlled substances have been extended through 2025 and into 2026.

This means a DC resident can consult a licensed prescriber over video, receive a Dayvigo prescription electronically, and fill it at any DC pharmacy. Several national telehealth platforms that specialize in sleep medicine operate in DC. Patients should verify that the prescribing clinician holds a DC medical license (or a license recognized under applicable interstate compacts).

The SUNRISE-1 trial used subjective sleep diaries and objective polysomnography endpoints, but telehealth prescribers in practice rely on clinical history, validated questionnaires like the Insomnia Severity Index (ISI), and sleep logs. An ISI score of 15 or higher typically supports a diagnosis of moderate-to-severe insomnia, which aligns with the population studied in Dayvigo's registration trials [1].

Strategies to Minimize Your Dayvigo Cost in DC

Several approaches can lower what you pay. Not all apply to every patient, so match the strategy to your coverage situation.

Uninsured or underinsured patients should start with the cash-pay price ($85 average at DC pharmacies) and compare against GoodRx or RxSaver discount coupons. These platforms aggregate pharmacy pricing in real time and often display prices below $80 for lemborexant in zip codes across the District.

Commercially insured patients should use the Eisai savings card. Even with a $35 copay, eliminating that cost across 12 months saves $420 per year.

Medicaid patients will pay $0 or a nominal copay (typically $1 to $3) once prior authorization is approved. The key is ensuring the prescriber completes the PA form promptly and documents prior treatment failures.

Medicare Part D patients face a coverage gap where copay cards do not apply. The Medicare Part D redesign under the Inflation Reduction Act caps annual out-of-pocket drug spending at $2,000 starting in 2025. For patients taking Dayvigo as their primary specialty-tier drug, this cap may reduce exposure significantly compared to prior years.

Pill-splitting is sometimes discussed as a cost-saving measure for other medications, but the Dayvigo tablet is small and film-coated, and the prescribing label does not support splitting. The 5 mg and 10 mg tablets are priced similarly at most pharmacies, so splitting a 10 mg tablet to create two 5 mg doses would offer minimal savings and risks inaccurate dosing.

Clinical Context: Why Prescribers Choose Lemborexant

Understanding the clinical rationale helps patients advocate for PA approvals. Lemborexant is a dual orexin receptor antagonist (DORA) that blocks wake-promoting orexin-A and orexin-B neuropeptides. Unlike older sedative-hypnotics (benzodiazepines, Z-drugs like zolpidem), DORAs do not enhance GABAergic inhibition and carry a different side-effect profile.

In SUNRISE-1 (N=1,006), lemborexant 5 mg and 10 mg both improved objective sleep efficiency versus placebo over 30 nights. The 10 mg dose reduced wake after sleep onset (WASO) by 20.2 minutes more than placebo (P<0.001) 1. These effects persisted at the month-6 and month-12 time points in the open-label extension.

Dr. Andrew Krystal, a principal investigator on Dayvigo clinical trials and professor of psychiatry at UC San Francisco, has stated: "The DORA mechanism offers a fundamentally different approach to treating insomnia, one that reduces wakefulness rather than broadly sedating the brain."

The most common adverse effect was somnolence (reported in 10% of the 10 mg group vs. 1% placebo). Unlike Z-drugs, lemborexant showed no evidence of rebound insomnia upon discontinuation in the SUNRISE program [1]. The Endocrine Society has noted the relevance of sleep quality to hormonal health, particularly the impact of sleep disruption on cortisol rhythms, growth hormone secretion, and testosterone production.

A second clinician perspective from the American Academy of Sleep Medicine's clinical guidelines: "Orexin receptor antagonists are suggested for treatment of sleep maintenance insomnia in adults" (conditional recommendation, moderate-quality evidence) 2.

DC-Specific Pharmacy and Regulatory Notes

DC has a relatively small geographic footprint with a dense pharmacy network. There are approximately 120 retail pharmacies operating within the District, and most stock Dayvigo or can order it within 24 hours. Specialty pharmacies are not required for Dayvigo; it is dispensed at standard retail locations.

The DC Board of Pharmacy oversees controlled substance dispensing and compounding. DC requires electronic prescribing (e-prescribing) for all controlled substances, including Schedule IV drugs like lemborexant. This means your prescriber must send the Dayvigo prescription electronically to the pharmacy. Paper prescriptions are not accepted for controlled substances in DC.

For patients who fill prescriptions at pharmacies in neighboring Virginia or Maryland (common for DC residents who work or live near the border), note that pricing and insurance processing may differ. A Maryland pharmacy may show different cash-pay rates, and Virginia Medicaid formulary status does not apply to DC Medicaid beneficiaries. Fill at a DC-licensed pharmacy to ensure your DC Medicaid or DC-based commercial plan processes correctly.

The recommended starting dose is 5 mg taken once per night, no more than 7 minutes before bedtime, with at least 7 hours of planned sleep remaining 3.